Business
Anixa Biosciences is an oncology biotechnology company developing therapies and vaccines, including lira-cel cell therapy and cancer vaccine programs.
Anixa had no standard revenue field in FY2025, the net loss narrowed to $10.9M, and cash from ops was -$7.2M.
The read at a glance✓ Audited against SEC data
- Business mix — Oncology therapies and vaccinesNote
- Revenue — Standard revenue field unavailableNote
- Profitability — Net loss narrowed 13.0%Note
- Cash — Cash from ops was -$7.2MWatch
- Balance sheet — Equity fell 24.2%Watch
- Insiders — 4 buys / 0 sells; cluster buyOK
- Accounting — Latest Altman-Z distressWatch
Where the revenue comes from
Fiscal 2019, as Anixa Biosciences Inc reports it. History and quarterly detail are in the app.
- Patent Licensing$250K
Latest filings
- 10-Q · Quarterly report2026-06-10
- 8-K · Company announcement2026-03-11
- 10-Q · Quarterly report2026-03-09
- 8-K · Company announcement2026-02-09
- DEF 14A · Annual proxy (pay & governance)2026-01-28
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Anixa Biosciences Inc, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.